Ultimately, CTS, the liposoluble compound in Danshen, was identified as a novel NPC1L1 inhibitor and significantly alleviated hepatic steatosis in HFD-fed NAFLD mice, suggesting that CTS may exert its protective effect against NAFLD by inhibiting NPC1L1 (Figure 6). Here, TTR is linked to metabolic dysfunction-associated steatotic liver disease.